ArQule, Inc. (NASDAQ:ARQL) – B. Riley dropped their Q4 2019 EPS estimates for ArQule in a report released on Friday, November 2nd. B. Riley analyst G. Zavoico now forecasts that the biotechnology company will earn $0.00 per share for the quarter, down from their prior forecast of $0.04. B. Riley currently has a “Buy” rating and a $7.00 target price on the stock.
A number of other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded shares of ArQule from a “hold” rating to a “buy” rating and set a $7.75 target price on the stock in a research report on Monday, July 9th. BidaskClub lowered shares of ArQule from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 12th. Finally, ValuEngine lowered shares of ArQule from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 31st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $6.85.
ArQule (NASDAQ:ARQL) last announced its earnings results on Wednesday, October 31st. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The business had revenue of $4.98 million for the quarter, compared to analysts’ expectations of $2.44 million. During the same quarter last year, the business posted ($0.09) earnings per share.
Large investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in ArQule in the 1st quarter valued at $100,000. CAPROCK Group Inc. purchased a new position in ArQule in the 2nd quarter valued at $109,000. Zebra Capital Management LLC purchased a new position in ArQule in the 2nd quarter valued at $115,000. State Board of Administration of Florida Retirement System purchased a new position in ArQule in the 2nd quarter valued at $169,000. Finally, Metropolitan Life Insurance Co. NY purchased a new position in ArQule in the 2nd quarter valued at $171,000. Hedge funds and other institutional investors own 65.37% of the company’s stock.
ArQule Company Profile
ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. It offers Derazantinib (ARQ 087), a multi-kinase inhibitor of the fibroblast growth factor receptor (FGFR) family that is in a registration trial in intrahepatic cholangiocarcinoma with FGFR2 fusions.
Recommended Story: Fiduciary
Receive News & Ratings for ArQule Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ArQule and related companies with MarketBeat.com's FREE daily email newsletter.